Avellino Labs, a global biotechnology and precision medicine company, has named Chris Lehman as its new chief financial officer, it was reported yesterday.

Lehman has more than twenty-five years of financial and transactional experience in the biotechnology industry and will lead all financial aspects of Avellino Labs' expansion of disruptive genetic diagnostic and therapeutic technologies. He has led or supported 30 plus partnering, financing and M&A transactions, totalling USD600+ million primarily at top-tier biotechnology industry companies, including Coherus Biosciences, Quintiles, and Genencor International (acquired by DuPont de Nemours, Inc), and most recently served as CFO for Eureka Therapeutics. In addition to his experience with these companies, he founded his own successful business development strategy consultancy.

Gene Lee, chairman of Avellino Labs, said, 'Chris's financial leadership is key to our next phase of growth and to the success of our IPO expected later this year on the Korean stock exchange. His experience in the biotech space and in communicating with investors will prove invaluable as we shape our strategies and implement the operational expertise required to leap forward in our comprehensive diagnostic, therapeutic and big data programs.'